Benazepril detailed information

Benazepril detailed information

Clinical data
Pregnancy category	D
Routes of administration	Oral
ATC code	C09AA07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	96.7%
Metabolism	Hepatic glucuronidation
Elimination half-life	10-11 hours
Excretion	Renal and biliary
Identifiers
IUPAC name 2-[(4S)-4-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl]amino]- 3-oxo-2-azabicyclo[5.4.0]undeca-7,9,11-trien-2-yl]acetic acid
CAS Number	86541-75-5
PubChem CID	5362124
DrugBank	APRD00063
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H28N2O5
Molar mass	424.49 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Benazepril, brand name Lotensin®, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.

Dosage forms

Oral tablets, 5 mg, 10 mg, 20 mg, and 40 mg.

Benazepril is also available in combination with hydrochlorothiazide, under the trade name Lotensin® HCT, and with amlodipine (trade name Lotrel®).

Side effects

Most commonly, headache and cough. Anaphylaxis and angioedema can occur. Hyperkalemia, or an elevation of potassium levels, can also occur.

Benazepril may cause harm to the fetus during pregnancy.

Contraindications

Benazepril should be discontinued during pregnancy.

Kidney disease

According to a 2006 article in the New England Journal of Medicine, patients with advanced renal insufficiency taking benazepril showed "substantial" kidney benefits.

A long term study of patients' kidney disease revealed that patients who took benazepril had better kidney function and a slower progression of kidney disease. Kidney function was much better in the group of patients taking the drug than their peers who took a placebo drug. This is notable because this category of pharmaceuticals have long been thought to cause further kidney damage or increase the rate of progression for kidney disease.

According to coverage of the study on WebMD:

ACE inhibitors can pose a potential threat to kidneys as well. The key question was whether damaged kidneys would worsen if patients took ACE inhibitors. In a nutshell, concerns centered on blood levels of potassium and creatinine, waste products that are excreted by the kidneys. Testing creatinine levels in the blood is used as a way to monitor kidney function (...) kidney problems worsened more slowly in those taking Lotensin. Overall, there were no major differences in side effects between patients taking Lotensin or the placebo.}}

This study marks the first indication that benazepril, and perhaps other ACE inhibitors, may actually be beneficial in the treatment of hypertension in patients with kidney disease.

Veterinary use

Under the brand name Fortekor (Novartis), benazepril hydrochloride is used to treat congestive heart failure in dogs and chronic renal failure in cats.

References

Template:ACE inhibitors

Template:WikiDoc Sources Template:SIB